Increased serum thymic stromal lymphopoietin levels in patients with cutaneous T cell lymphoma
T. Miyagaki,M. Sugaya,H. Fujita,H. Saeki,K. Tamaki
DOI: https://doi.org/10.1111/j.1365-2230.2008.02990.x
2009-06-01
Abstract:Thymic stromal lymphopoietin (TSLP) was first cloned from a murine thymic stromal cell line. Human TSLP potently activates immature CD11c-positive myeloid dendritic cells (DCs), which create a T-helper (Th)-2-permissive microenviroment. In vivo, TSLP has been shown to be strongly expressed by keratinocytes in acute and chronic lesions of atopic dermatitis (AD), but not expressed in normal skin or nonlesional skin in patients with AD. There has been, however, no report studying serum TSLP levels in patients with skin diseases. The medical ethics committee approved the study, and informed consent was obtained from all subjects. In total, 13 patients with AD (mean ± SD age 31.1 ± 14.5 years), 12 patients with psoriasis (56.9 ± 14.3 years), 29 patients with cutaneous T-cell lymphoma (CTCL) (58.0 ± 13.9 years; 26 cases of mycosis fungoides and 3 cases of Sézary syndrome), and 22 healthy control subjects (44.0 ± 17.5 years) were enrolled in the study. Immunoreactive TSLP in sera was quantified using a human TSLP ELISA kit (R & D systems. Minneapolis, MN, USA) as previously described. Statistical analysis between two groups was performed using the Mann–Whitney U-test. Serum TSLP levels of patients with AD and those with psoriasis were 36.4 ± 4.2 and 35.3 ± 5.1 pg ⁄ mL, respectively (Fig. 1), and were not significantly different from healthy controls (34.2 ± 4.1 pg ⁄ mL) (P > 0.05). The serum TSLP level of patients with CTCL was 40.1 ± 5.0 pg ⁄ mL, which was significantly higher than that of controls (P < 0.01). Serum TSLP levels greater than the mean + 2SD of the control serum samples (dotted line in Fig. 1) were considered to be raised. The percentage of increased samples was 7.7% in AD, 27.6% in CTCL and 8.6% in psoriasis. We next studied TSLP levels at different stages of CTCL (Fig. 2). Interestingly, the percentages of increased samples were greater in the early stages (patch stage 37.5%, plaque stage 25%, tumour stage 0%, erythroderma 25%), when tumour cells have more interaction with epidermal keratinocytes. Serum TSLP levels were not correlated with age, lactate dehydrogenase levels, or other clinical and laboratory data. TSLP triggers dendritic cell-mediated Th2-type inflammatory responses and is considered to be a master switch for allergic inflammation. We found that, surprisingly, serum TSLP levels were not increased in patients with AD. In addition, the levels were not decreased in patients with psoriasis, a common Th1-type skin disease. It suggests that TSLP produced by keratinocytes may be active only in the skin, without being released in peripheral blood. Serum TSLP levels were increased in patients with CTCL, a cutaneous malignancy of lymphocytes. TSLP was recently reported to directly induce T-cell proliferation, suggesting a direct effect on lymphoma cells. Because serum TSLP levels were slightly decreased as tumour cells penetrated deeper into the dermis, it is possible that tumour cells depend on TSLP from keratinocytes for their proliferation in the early stages and that they become independent at a late stage. A more detailed study would reveal the role of TSLP in the pathogenesis of CTCL. Figure 1 Serum levels of thymic stromal lymphopoietin (TSLP) in patients with psoriasis vulgaris, atopic dermatitis (AD), or cutaneous T-cell lymphoma (CTCL) and in healthy controls. Dots indicate the measured values from individual patients, with the bars being the mean of each group and the dotted horizontal line being the cut-off value (mean + 2SD of the control samples). *P < 0.01 by Mann–Whitney U-test.